Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 502

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 502
---
,
and (ii) August Warrants to purchase an aggregate of up to 1,136,391 shares of Common Stock, at the reduced exercise price of $0.58 per
share. We received aggregate gross proceeds of approximately $1.4 million, before deducting advisory fees and other expenses payable
by us. In consideration of the immediate exercise of the October Warrants and August Warrants by the holders thereof in accordance with
the February Inducement Agreement, we issued unregistered common warrants to purchase an aggregate of up to 2,926,166 shares of Common
Stock (120% of the number of shares of Common Stock issuable upon exercise of the October Warrants and August Warrants) to such holders.

October
2024 Registered Direct Offering and Concurrent Private Placement

On
October 21, 2024, we issued to certain institutional investors (i) in a registered direct offering, 2,048,294 shares of our Common Stock,
and (ii) in a concurrent private placement, common warrants to purchase an aggregate of 2,662,782 shares of Common Stock, with an exercise
price of $1.50, pursuant to a securities purchase agreement, dated October 18, 2024, that we entered into with such institutional investors,
and received aggregate gross proceeds from the offerings of approximately $2.7 million, before deducting placement agent fees and other
offering expenses.

August
2024 Warrant Inducement, Registered Director Offering and Concurrent Private Placement

On
August 5, 2024, pursuant to the terms of the August Inducement Agreement, certain holders of existing warrants, exercised for cash March
Warrants to purchase an aggregate of up to 1,041,667 shares of Common Stock, at the reduced exercise price of $1.25 per share. We received
aggregate gross proceeds of approximately $1.3 million, before deducting advisory fees and other expenses payable by us. In consideration
of the immediate exercise of the March Warrants by the holders thereof in accordance with the August Inducement Agreement, we issued
unregistered common warrants to purchase an aggregate of up to 1,302,082 shares of Common Stock (120% of the number of shares of Common
Stock issuable upon exercise of the March Warrants) to such holders.

On
August 5, 2024, we also issued to an institutional investor (i) in a registered direct offering, 360,000 shares of Common Stock,